Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 7:8:336.
doi: 10.3389/fmicb.2017.00336. eCollection 2017.

Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Ana C O Souza  1 , Andre C Amaral  2
Affiliations
Review

Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Ana C O Souza et al. Front Microbiol. .

Abstract

Fungal diseases have been emerging as an important public health problem worldwide with the increase in host predisposition factors due to immunological dysregulations, immunosuppressive and/or anticancer therapy. Antifungal therapy for systemic mycosis is limited, most of times expensive and causes important toxic effects. Nanotechnology has become an interesting strategy to improve efficacy of traditional antifungal drugs, which allows lower toxicity, better biodistribution, and drug targeting, with promising results in vitro and in vivo. In this review, we provide a discussion about conventional antifungal and nanoantifungal therapies for systemic mycosis.

Keywords: antifungal therapy; drug delivery systems; fungal infection; mycosis; nanobiotechnology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Benefits of nanobiotechnology approaches for delivery of antifungal drugs.
Figure 2
Figure 2
Schematic representation of different types of nanoparticles used for the delivery of antifungal agents.
See this image and copyright information in PMC

References

    1. Adler-Moore J. (1994). AmBisome targeting to fungal infections. Bone Marrow Transplant. 14(Suppl. 5), S3–S7. - PubMed
    1. Adler-Moore J. P., Gangneux J. P., Pappas P. G. (2016). Comparison between liposomal formulations of amphotericin B. Med. Mycol. 54, 223–231. 10.1093/mmy/myv111 - DOI - PubMed
    1. Agger E. M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B. S., Aagaard C., et al. . (2008). Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 3:e3116. 10.1371/journal.pone.0003116 - DOI - PMC - PubMed
    1. Albasarah Y. Y., Somavarapu S., Stapleton P., Taylor K. M. (2010). Chitosan-coated antifungal formulations for nebulisation. J. Pharm. Pharmacol. 62, 821–828. 10.1211/jpp.62.05.0002 - DOI - PubMed
    1. Amaral A. C., Bocca A. L., Ribeiro A. M., Nunes J., Peixoto D. L., Simioni A. R., et al. . (2009). Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis. J. Antimicrob. Chemother. 63, 526–533. 10.1093/jac/dkn539 - DOI - PubMed